Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
05 août 2024 07h30 HE
|
Rezolute, Inc.
Second rare disease program with RZ358 in Phase 3 development Follows successful treatment of multiple patients with tumor hyperinsulinism under the Company’s Expanded Access Program REDWOOD CITY,...
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
31 juil. 2024 08h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel,...
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
27 juin 2024 08h00 HE
|
Rezolute, Inc.
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative...
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
24 juin 2024 08h00 HE
|
Rezolute, Inc.
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative...
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
13 juin 2024 23h30 HE
|
Rezolute, Inc.
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative...
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
13 juin 2024 16h01 HE
|
Rezolute, Inc.
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative...
Rezolute to Participate in the Jefferies Global Healthcare Conference
30 mai 2024 08h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel,...
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
21 mai 2024 16h05 HE
|
Rezolute, Inc.
Met primary study endpoints: good safety profile and reduction in central subfield thickness (CST) First oral therapy to demonstrate reduction in macular edema; supports potential for early disease...
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
15 mai 2024 16h05 HE
|
Rezolute, Inc.
Patient enrollment underway in sunRIZE global Phase 3 clinical study of RZ358 in patients with congenital hyperinsulinism (cHI); topline results expected in mid-2025 Completed in-vivo toxicology...
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
23 avr. 2024 08h00 HE
|
Rezolute, Inc.
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company committed to developing novel,...